Edwards Lifesciences Global Medical Device Registrations Dossier

A global registry dossier for Edwards Lifesciences, analyzing medical device registrations across US FDA, Canada MDALL, Australia ARTG, EU EUDAMED, and other major markets.

Global Regulatory Dossier: Edwards Lifesciences

For regulatory affairs (RA) professionals, clinical specialists, and competitive intelligence (CI) analysts, mapping the global regulatory footprint of Edwards Lifesciences provides an essential case study in structural-heart focus. Unlike highly diversified medtech conglomerates, Edwards Lifesciences has historically maintained a highly concentrated portfolio. As the pioneer and global leader in transcatheter heart valves (including transcatheter aortic valve replacement, or TAVR) and surgical structural-heart therapies, Edwards' global device registrations are premium, high-value regulatory assets.

This global dossier analyzes the distribution of Edwards Lifesciences' product registrations across major international medical device databases. By compiling data from national registries in the United States, Canada, Australia, the European Union, and other key global markets, we examine where Edwards holds active registrations, how its core platforms—specifically the SAPIEN TAVR platform, RESILIA surgical tissue valves, PASCAL transcatheter valve repair systems, EVOQUE tricuspid valve replacement systems, and the newly approved SAPIEN M3 mitral valve—are mapped to databases, and how its recent strategic transactions, including the 2024 Critical Care divestiture to Becton Dickinson (BD), have reshaped its regulatory profile.

Scenario Question & Direct Answer

What does Edwards Lifesciences' medical-device registration footprint look like across the US, EU, Canada, and Australia, and how do its SAPIEN, PASCAL, EVOQUE, RESILIA, and SAPIEN M3 products map to those registries?

Edwards Lifesciences' global medical device registrations reflect its highly focused structural-heart portfolio, showing active manufacturer-level records across major international databases. As of mid-2026, registry snapshots show 354 active FDA establishment registration/listing records in the United States, 353 active device licenses in Canada's MDALL, 132 active entries in Australia's ARTG, and 5 actor registrations plus 1 certificate in the EU's EUDAMED database. This focused footprint is anchored by the SAPIEN TAVR platform, which has treated over 1.2 million patients globally. SAPIEN, EVOQUE, PASCAL, and RESILIA platforms map to Class III (US FDA) and Class IV/Class D (Canada/EU) high-risk classifications, while the newly approved SAPIEN M3 transseptal mitral valve (FDA-approved in December 2025) is beginning to populate registries. The 2024 divestiture of its Critical Care business unit to BD for $4.2 billion (closed September 3, 2024) — a business that had represented close to a fifth of Edwards' pre-divestiture net sales — transferred the associated hemodynamic monitoring registrations to BD's regulatory accounts. Channel data indicates Edwards operates through direct subsidiaries in major markets (US, Canada, Europe, Australia, Japan, Brazil), while partnering with local representatives in smaller territories.

The Global Evidence Map: Positive Registry Matches

To construct a reliable map of Edwards Lifesciences' global regulatory footprint, we queried major international medical device databases. The table below represents positive matches where Edwards Lifesciences or its verified brand entities are listed as the manufacturer, sponsor, applicant, or license holder.

Jurisdiction / Market	Database Source	Matching Records	Manufacturer / Licensee Entity Values Identified	Classification
United States	FDA CDRH (Registration & Listing)	354	Edwards Lifesciences LLC; Edwards Lifesciences Technology SARL; Edwards Lifesciences AG (CCT)	POSITIVE
Canada	Health Canada MDALL Active Licenses	353	Edwards Lifesciences LLC	POSITIVE
Australia	TGA Australian Register of Therapeutic Goods (ARTG)	132	Edwards Lifesciences Pty Ltd (Sponsor); Edwards Lifesciences LLC (Manufacturer)	POSITIVE
European Union	EUDAMED Public Devices & Actors	5 (Actors) / 1 (Cert)	Edwards Lifesciences LLC; Edwards Lifesciences Services GmbH	POSITIVE

[!NOTE] Counts are brand-token matches against each registry's manufacturer/licensee/sponsor name field in point-in-time snapshots (FDA: 2026-06-10; Canada MDALL: 2026-06-05; Australia ARTG: 2026-06-05; EUDAMED actors: 2026-06-18; EUDAMED certificates: 2026-06-10). A registry "record" is a registration or license line, not a unique SKU. Beyond these four core registries, Edwards also holds registrations in additional markets (including Brazil, Colombia, Saudi Arabia, South Korea, Taiwan, Singapore, and India) through local subsidiaries and authorized representatives; those national databases use heterogeneous schemas and are not summed here to avoid double-counting. The FDA figure includes a small number of records under the "Edwards Lifesciences AG / CCT Critical Care Technologies" entity associated with the Critical Care unit divested to BD in September 2024.

Registry Limitations & No-Hit Analysis

When conducting global regulatory intelligence sweeps, identifying where data is constrained or where technical caveats apply is critical. The table below outlines the databases inspected where Edwards Lifesciences has data limitations.

Jurisdiction	Database Inspected	Finding / Status	Technical Caveat / Database Limitation
Switzerland	swissdamed (UDI Details)	LIMITATION	swissdamed's public UDI database contains limited records for Edwards, as the registry is in a phased implementation. Active Swiss registrations are maintained but not fully visible in public queries.
European Union	EUDAMED Certificates	LIMITATION (1 Cert)	Only 1 active certificate is visible under Edwards-associated Actor IDs in EUDAMED. This reflects the delayed mandatory status of the EUDAMED Certificates module, which only became mandatory on May 28, 2026, meaning many notified bodies are still uploading legacy MDR certificates.
Oman	MOH Medical Devices	NO-HIT (Data Gap)	The database is restricted to local licensed sponsors; no public-facing search tool is available to extract manufacturer-specific listings.
Jordan	JFDA Medical Devices List	LIMITATION	Records are listed primarily at the local distributor level under brand names, making direct manufacturer queries incomplete.

Understanding Registry Data Limits: A Commercial Warning

A critical mistake made by market analysts, investors, and regulatory consultants is treating medical device registration records as equivalent to market share, product sales, or clinical usage. It is critical to recognize the inherent limits of registry datasets:

Registrations are Not Sales: An active registration simply indicates that a device has cleared regulatory hurdles and is legally allowed to be commercialized in that country. It does not mean the device is actively marketed, stocked, or utilized in local clinical settings. Edwards Lifesciences maintains active registrations for legacy surgical heart valves (such as older Carpentier-Edwards models) in various international markets, even if those markets have largely transitioned to newer RESILIA-tissue valves.
Record Counts do Not Equal Unique SKUs: The unit of measurement in registries is the "record" or "line count". A single registration record (or license) can cover hundreds of individual catalog numbers (SKUs), packaging sizes, or product configurations. Conversely, a single product line might be split across multiple registration records due to variations in manufacturing sites or component classifications.
Vigilance and Recalls reflect Report Counts, not Safety Incidence: In public safety databases, counts reflect administrative actions and reporting volume. Because Edwards' transcatheter valves are implanted in high-risk patients with severe aortic stenosis, the clinical complexity of this patient population naturally leads to a high volume of adverse event reporting, which is a reflection of clinical vigilance and patient risk, not a higher defect rate.
Distributor Lists are Channel Evidence, Not Approvals: In databases listing authorized importers or distributors, the presence of an Edwards entity indicates a commercial channel setup rather than a technical product approval. A local distributor must be licensed to import, but they can only import products that have separately secured technical registration certificates.

Core Structural-Heart Portfolio & Registry Mapping

Edwards Lifesciences' commercial and regulatory strength lies in its structural-heart portfolio. Analyzing global device registries provides empirical evidence of how its core platforms are registered and maintained.

graph TD
    EL[Edwards Lifesciences] --> THV[Transcatheter Heart Valves]
    EL --> SHV[Surgical Heart Valves]
    EL --> TMTT[Transcatheter Mitral & Tricuspid]
    
    THV --> SAPIEN[SAPIEN TAVR Platform]
    SHV --> RESILIA[RESILIA Surgical Valves]
    TMTT --> PASCAL[PASCAL Repair System]
    TMTT --> EVOQUE[EVOQUE Replacement]
    TMTT --> SAPIENM3[SAPIEN M3 Mitral Valve]

1. SAPIEN TAVR Platform (Aortic Valve)

The SAPIEN platform represents the cornerstone of Edwards' business, with more than 1.2 million patients treated worldwide.

Registry Representation: In the US FDA database, the SAPIEN platform is registered under Class III pre-market approvals (PMAs), starting with the foundational first-generation SAPIEN valve approved under P100041 on November 2, 2011 (the first US TAVR approval, for inoperable patients), with later-generation SAPIEN XT, SAPIEN 3, and SAPIEN 3 Ultra / Ultra RESILIA approvals tracked under successor PMA numbers and supplements. In Canada's MDALL, the SAPIEN 3 and SAPIEN 3 Ultra systems represent the highest-volume active Class IV licenses for Edwards.
Regulatory Milestones: Edwards has consistently expanded the clinical indications for the SAPIEN platform:
- 2007: First commercial CE mark approval in Europe.
- November 2011: First US FDA approval for inoperable patients.
- August 16, 2019: FDA approval for low-risk patients (SAPIEN 3 and SAPIEN 3 Ultra).
- May 2025: First FDA TAVR approval for patients with asymptomatic severe aortic stenosis, based on the results of the EARLY TAVR trial.
- December 2025: FDA approval of the SAPIEN M3 transseptal mitral valve, expanding the SAPIEN platform to transcatheter mitral valve replacement (TMVR).

2. RESILIA Surgical Valves

RESILIA tissue technology represents Edwards' proprietary anti-calcification platform, utilized in surgical aortic valves (Inspiris Resilia), mitral valves (Konect Resilia), and surgical conduits.

Registry Representation: RESILIA valves map to Class III (FDA) and Class IV (Health Canada) registries. In Australia's ARTG, the Inspiris Resilia valve holds dedicated listings under sponsor Edwards Lifesciences Pty Ltd.

3. PASCAL Transcatheter Valve Repair System

The PASCAL system utilizes a spacer and paddles to grasp valve leaflets, competing directly with Abbott's MitraClip for transcatheter mitral and tricuspid valve repair.

Registry Representation: PASCAL holds active Class IV licenses in Canada MDALL and active Class III PMAs in the US (the PASCAL Precision system received FDA approval for degenerative mitral regurgitation in 2022, with subsequent tricuspid-repair expansions).

4. EVOQUE Tricuspid Valve Replacement System

EVOQUE represents the first transcatheter valve replacement system to receive FDA approval (February 1, 2024, under PMA P230013) for the treatment of severe tricuspid regurgitation.

Registry Representation: EVOQUE listings are actively expanding across major global registries, serving as a key differentiator for Edwards, as competitors are still in clinical trial phases or early rollouts for tricuspid replacement.

Detailed Market Profiles & Registry Insights

To understand Edwards' regulatory footprint, we must look beyond numbers and inspect how Edwards is represented in specific key databases.

1. United States: FDA CDRH Database

The United States represents Edwards' largest market. The FDA Registration & Listing snapshot shows the manufacturing footprint behind Edwards' US presence:

FDA Registration & Listing: Out of 417,036 total registered establishments and listing records in the snapshot, 354 records match Edwards Lifesciences entities. The largest establishment names include Edwards Lifesciences Technology SARL (Switzerland), Edwards Lifesciences LLC (Irvine, CA), and the CCT Critical Care Technologies / Edwards Lifesciences AG entity (Costa Rica / Switzerland) associated with the divested Critical Care unit.
FDA PMA: Edwards' high-risk Class III portfolio is anchored in the PMA database by the SAPIEN TAVR family (originating with P100041, approved November 2, 2011), the EVOQUE tricuspid system (P230013, approved February 1, 2024), and the SAPIEN M3 mitral system (P250019, approved December 22, 2025), each carrying a long tail of indication-expansion supplements.
FDA 510(k): Edwards' 510(k) footprint is comparatively small and concentrated in surgical accessories, annuloplasty rings, cardiac cannulae, and legacy cardiovascular instruments, reflecting its focus on PMA-class implantable valves rather than 510(k)-cleared devices.

2. Canada: Health Canada MDALL

Health Canada's Medical Devices Active License Listing (MDALL) tracks active licenses for Class II, III, and IV medical devices:

Denominator: 152,560 active license records.
Combined Edwards Matches: 353 active licenses.
Analysis: Because Health Canada requires separate licenses for each device system, Edwards' active licenses are highly concentrated in Class IV (high-risk implantable) devices, representing the SAPIEN TAVR systems, RESILIA tissue valves, and annuloplasty rings.
Subsidiary Breakdown: In the MDALL snapshot, Edwards' active licenses are held almost entirely under a single legal manufacturer entity — Edwards Lifesciences LLC (Irvine, CA) — rather than spread across multiple subsidiaries.

3. Australia: TGA ARTG

The Australian Register of Therapeutic Goods (ARTG) is the repository of all medical devices approved for supply in Australia.

Denominator: 99,405 records.
Combined Edwards Matches: 132 sponsor or manufacturer listings.
Analysis: The database shows Edwards Lifesciences Pty Ltd (the local Australian subsidiary based in North Ryde, NSW) as sponsor for the large majority of Edwards' entries, with Edwards Lifesciences LLC (USA) as the manufacturer of record.
Sample Entry: A typical listing pattern is a SAPIEN 3 transcatheter heart valve entry, with Edwards Lifesciences Pty Ltd as sponsor and Edwards Lifesciences LLC (USA) as manufacturer.

4. European Union: EUDAMED Registry

Under the EU MDR, EUDAMED mandatory actor registration began on May 28, 2026, for the first four modules.

Actor Registrations: Edwards Lifesciences has registered 5 distinct Actor records (Single Registration Numbers, or SRNs) across Europe, representing its manufacturing sites and European sales offices (e.g., Edwards Lifesciences Services GmbH in Germany).
Certificate Visibility: In the Certificates module, Edwards currently shows 1 active MDR certificate. Similar to other manufacturers, this low count is a common industry-wide limitation: because the Certificates module is in its initial mandatory phase, notified bodies are prioritizing uploading certificates for new products over legacy MDD-to-MDR transition certificates.

Strategic Portfolio Reshaping: Divestitures and Acquisitions

Edwards Lifesciences' registry footprint has undergone significant changes due to strategic portfolio reshaping.

1. The Critical Care Divestiture to BD

In one of the largest medtech transactions of 2024, Edwards announced the divestiture of its Critical Care business unit to Becton, Dickinson and Company (BD) for $4.2 billion in cash. The transaction closed on September 3, 2024.

Portfolio Impact: The Critical Care unit, which includes hemodynamic monitoring systems (such as Swan-Ganz pulmonary artery catheters, FloTrac sensors, and HemoSphere monitoring platforms), had represented close to a fifth of Edwards' pre-divestiture net sales and a meaningful share of its historical registration footprint.
Registry Transition: Following the close of the transaction, BD took ownership of all related device registrations. In global databases, these registrations have transitioned to BD's legal entities. This explains why Edwards' active registry counts in mid-2026 are lower than historical baseline counts from early 2024. For a view of where these monitoring systems now reside, see the BD global medical device registrations dossier.

2. Acquisitions: JC Medical (J-Valve) & Vectorious

Following the Critical Care divestiture, Edwards redeployed capital to strengthen its structural-heart pipeline:

JC Medical (J-Valve): In August 2024, Edwards acquired JC Medical (a subsidiary of Genesis MedTech) for the development and commercialization of the J-Valve transcatheter aortic valve system, specifically designed for patients with aortic regurgitation. This acquisition added a specialized TAVR platform to Edwards' pipeline, which is beginning to appear in clinical and regulatory registry listings.
Vectorious MedTech: In September 2025, Edwards acquired the remaining outstanding shares of Vectorious MedTech, gaining ownership of its implantable, wireless left-atrial pressure sensor (V-LAP) for heart failure management. This acquisition marks Edwards' entry into implantable digital health monitoring, introducing new sensor-class product codes to its registry footprint.

Sourcing and Supply Chain Integration

Edwards Lifesciences' manufacturing network is highly globalized, which introduces unique regulatory and logistical dependencies. By analyzing the country of origin listed in global registries, we can map Edwards' manufacturing hubs:

Valves and Implants (Irvine, USA & Singapore): The TGA and ANVISA databases show that the SAPIEN TAVR valves and RESILIA tissue valves are primarily manufactured in Irvine, California, and Singapore. The Singapore facility (Changi) is a major global hub for advanced tissue heart valve manufacturing, where specialized technicians manually assemble the valves.
Surgical Annuloplasty Rings (Cartago, Costa Rica): Registration details from the CDSCO and Health Canada reveal that a significant portion of Edwards' annuloplasty rings and surgical accessories are manufactured in Cartago, Costa Rica. Costa Rica has become a critical low-cost, high-quality medical manufacturing hub.
Hardware and Monitors (Draper, USA): Hemodynamic monitoring hardware (pre-divestiture) and tissue valve delivery systems are primarily manufactured in Draper, Utah.

For supply chain managers, this distribution highlights the risk of tariff exposure. Products imported into the US from Edwards' Singapore facilities face different tariff schedules compared to domestic US production.

Peer Comparison: Edwards vs. Competitors

To contextualize Edwards' regulatory footprint, we compare its registry metrics against other major cardiovascular and structural-heart competitors. Edwards' focused structure contrasts with the diversified portfolios of its peers.

Edwards vs. Boston Scientific: Boston Scientific competes directly with Edwards in the structural-heart segment (TAVR) via the Acurate neo2 platform and its recent investments (such as the JenaValve acquisition, which was blocked by the FTC in 2024 but remains a key competitive focal point). Boston Scientific maintains a significantly larger total registration footprint due to its extensive endoscopy, urology, and neuromodulation portfolios. For details on Boston Scientific's regulatory footprint, see the Boston Scientific FDA device footprint.
Edwards vs. Abbott: Abbott is Edwards' primary competitor in transcatheter mitral and tricuspid valve repair (MitraClip vs. PASCAL). Abbott holds a vastly larger registration footprint due to its coronary stent, cardiac rhythm management (pacemaker), and in vitro diagnostics (IVD) portfolios. For details on Abbott's regulatory footprint, see the Abbott FDA device footprint.
Edwards vs. J&J (Abiomed): J&J's cardiovascular footprint is centered on the Abiomed Impella heart-recovery pumps and Biosense Webster electrophysiology catheters. J&J's cardiovascular registrations are highly specialized and complementary to Edwards' valve portfolios, representing mechanical circulatory support and arrhythmia mapping rather than valve replacement. For details on J&J's regulatory footprint, see the J&J MedTech global medical device registrations dossier.
Edwards vs. BD: Following the 2024 Critical Care transaction, BD took ownership of Edwards' hemodynamic monitoring portfolio. BD holds a massive footprint in high-volume, low-risk consumables (syringes, needles, pre-analytical collection tubes) and diagnostic reagents. For details, see the BD global medical device registrations dossier.

FAQs

When was SAPIEN first approved and what are its key FDA milestones?

The SAPIEN platform received its first commercial CE mark approval in Europe in 2007. Key FDA milestones include:

November 2011: First FDA approval of SAPIEN for inoperable aortic stenosis patients.
August 2019: FDA approval of SAPIEN 3 and SAPIEN 3 Ultra for low-risk patients.
May 2025: FDA approval of SAPIEN 3 for patients with asymptomatic severe aortic stenosis.
December 2025: FDA approval of the SAPIEN M3 transseptal mitral valve.

Does Edwards register directly or via local representatives outside the US?

Edwards utilizes a direct subsidiary model in all major, high-volume markets. Registrations are held by local subsidiaries such as Edwards Lifesciences Pty Ltd in Australia, Edwards Lifesciences Comércio de Produtos Médicos Ltda in Brazil, and Edwards Lifesciences Colombia S.A.S. In smaller markets or regions with complex distribution laws, Edwards partners with local authorized representatives who manage local customs clearances.

How many Edwards actor/certificate records are visible in EUDAMED?

Edwards Lifesciences has registered 5 distinct Actor records (Single Registration Numbers, or SRNs) in EUDAMED. Currently, 1 active MDR certificate is visible under these actor profiles in the public database, which is an industry-wide limitation resulting from the delayed uploading of legacy transition certificates by notified bodies following the May 28, 2026, EUDAMED mandate.

What did Edwards acquire and divest recently?

Divestiture: Edwards divested its Critical Care business unit to BD for $4.2 billion in cash; the transaction closed on September 3, 2024.
Acquisitions: Edwards acquired JC Medical (J-Valve) in August 2024 and purchased the remaining outstanding shares of Vectorious MedTech in September 2025.

Why is the 2024 Critical Care divestiture to BD considered a major structural shift for Edwards?

The divestiture of Critical Care for $4.2 billion marked a formal transition for Edwards into a pure-play structural heart company. Hemodynamic monitoring was historically a foundational pillar of Edwards, dating back to the Swan-Ganz catheter developed in the 1970s. By selling this division to BD, Edwards freed up significant capital to invest in high-growth, high-risk transcatheter mitral and tricuspid therapies (TMTT) and next-generation TAVR designs (such as the SAPIEN X4 platform). In global registries, this transaction required transitioning dozens of established monitoring system and catheter licenses to BD's legal manufacturer accounts.

What is the clinical and regulatory significance of the SAPIEN M3 approval?

The FDA approval of the SAPIEN M3 system in December 2025 represents the first transcatheter mitral valve replacement (TMVR) system approved for transseptal delivery. Mitral valve replacement has historically been restricted to open-heart surgery or transapical access due to the complex anatomy of the mitral valve. The transseptal approach allows the valve to be delivered via the femoral vein and across the septum, significantly reducing patient trauma and recovery time. In registries like Canada MDALL and Australia ARTG, the SAPIEN M3 is classified as a Class IV high-risk active implantable device, requiring dedicated post-market clinical follow-up (PMCF) registries to track long-term durability and leaflet thrombosis risks.

Internal Links and Context

For more information on cardiovascular M&A transactions, see the Cardiovascular device M&A deals guide.
For information on general market access frameworks, see the USA medical device registration US agent pricing guide.
For details on the blocked JenaValve acquisition, read the FTC blocks Edwards/JenaValve acquisition analysis.
To see how Edwards' divested portfolio is integrated, read the BD global medical device registrations dossier.